Skip to main content
. 2017 May 29;7(1):27–31. doi: 10.3892/mco.2017.1272

Figure 1.

Figure 1.

Clinical course of patients with PIK3CA (+) refractory cancer during the follow-up period. (no. 1) The PFS was 1.9 months. The patient succumbed to disease progression. (nos. 2 and 3) Patient no. 2 received sirolimus for 2.5 months and no. 3 received sirolimus for 0.9 months. The two patients were finally transferred to another hospital for supportive care. (no. 4) The PFS was 3.6 months. The patient succumbed to disease progression and sepsis. PFS, progression free survival; SD, stable disease; PD, progressive disease.